
TOKYO -- Takeda Pharmaceutical on Tuesday said it will raise nearly half of the 46 billion pounds ($62.3 billion) for the Shire buyout from a bridge loan but assured shareholders that it would deleverage rapidly to keep its investment-grade credit rating.
Takeda said on Tuesday that its shareholders had agreed to buy Ireland-based drugmaker Shire in a cash and stock deal, moving closer to sealing the biggest-ever overseas acquisition by a Japanese company. If the deal goes through, it will put Takeda among the world's top 10 drugmakers by revenue.